Modality
Gene Therapy
MOA
SHP2i
Target
TNFα
Pathway
Ferroptosis
DravetIPFLGS
Development Pipeline
Preclinical
~Oct 2018
→ ~Jan 2020
Phase 1
~Apr 2020
→ ~Jul 2021
Phase 2
Oct 2021
→ Jun 2031
Phase 2Current
NCT04032419
1,543 pts·LGS
2021-10→2031-06·Active
1,543 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-06-085.2y awayPh2 Data· LGS
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P2
Active
Catalysts
Ph2 Data
2031-06-08 · 5.2y away
LGS
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04032419 | Phase 2 | LGS | Active | 1543 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| Doxacagene | Sanofi | Approved | PSMA | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| VRT-1576 | Vertex Pharma | Phase 2/3 | RET | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Sovafutibatinib | Moderna | Approved | FcRn | |
| Sovanaritide | Argenx | Phase 3 | TNFα | |
| Daratuximab | BioMarin | Phase 1 | PRMT5 | |
| Nirafotisoran | Jazz Pharma | Phase 2/3 | TROP-2 |